Early Access to Promising Medicines – Real World Experience of PRIME & PIM Applications
Since 2014, there has been a welcome recognition within Europe of the need for improved regulatory mechanisms whereby medicines being developed to target serious or life-threatening diseases that represent an unmet clinical need can be made available to patients at